Clinical Research Directory
Browse clinical research sites, groups, and studies.
52-week Open Label Safety-Tolerability Study
Sponsor: LB Pharmaceuticals Inc.
Summary
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Official title: A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
900
Start Date
2026-04
Completion Date
2029-04
Last Updated
2026-05-15
Healthy Volunteers
No
Conditions
Interventions
LB-102
LB-102 flexible dosing 50 mg - 100 mg
Locations (23)
Chandler Clinical Trials
Chandler, Arizona, United States
Pillar Clinical Research
Bentonville, Arkansas, United States
Pillar Clinical Research
Little Rock, Arkansas, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Advanced Research Center
Anaheim, California, United States
Synapse Clinical Trials
Cerritos, California, United States
ProScience Research Group
Culver City, California, United States
CenExel
Culver City, California, United States
Synergy San Diego
San Diego, California, United States
CenExel
Hollywood, Florida, United States
Segal Trials
Miami Lakes, Florida, United States
Health Synergy Clinical Research
West Palm Beach, Florida, United States
CenExel
Atlanta, Georgia, United States
Accelerated Clinical Trial
Snellville, Georgia, United States
Pillar Clinical Research
Chicago, Illinois, United States
CenExel Gaithersburg
Gaithersburg, Maryland, United States
Arch Clinical Trials
St Louis, Missouri, United States
Redbird Research
Las Vegas, Nevada, United States
Neuro-Behavioral Clinical Research
New York, New York, United States
Neuro-Behavioral Clinical Research
Canton, Ohio, United States
Adams Clinical
Philadelphia, Pennsylvania, United States
Adams Clinical
DeSoto, Texas, United States
Pillar Clinical Research
Richardson, Texas, United States